spacer
home > ebr > autumn 2018 > determining peptides
PUBLICATIONS
European Biopharmaceutical Review

Determining Peptides

Therapeutic peptides are often applied via the following routes: intramuscular (IM), intraperitoneal (IP), intravenous (IV), or inhalative. Only a few peptides are stable in the stomach (acidic plus pepsin digestion) and the intestine (trypsin digestion) after oral application. Determination in plasma is very complex, as far as selectivity is concerned, because millions of endogenous peptides and proteins can be found in plasma.

Usually, the determination of a drug in plasma starts with some questions:

How much of that drug is applied per kg body weight
Which route of application is used (IM, IP, IV, oral, or inhalative)
Is anything known about the first pass effect (leading to metabolites and, therefore, lowering the parent drug concentration)
Does the molecule show a high volume of bodily distribution (which often means that the molecule shows very lipophilic characteristics or high tissue attraction and, therefore, a fast elimination half-life and low concentration levels in plasma

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Hermann Mascher, bioanalytical consultant and founder of pharm-analyt Labor, has more than 100 publications in peer reviewed journals (with more than a 230 impact factor). Hermann is the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases and has developed analytical methods for dozens of peptides.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biosimilar Drug Development the analytical strategy is keyfactor for your success

Heilbronn/Dortmund March 2019: The generation of analytical data for the comparison between a biosimilar and the originator product is the initial assumption in the development of biosimilars. Achieving Biosimilarity can be a controversial and complex topic when deciding the right time point and range of analytics.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement